%0 Journal Article
%T Intensive patient¡¯s care program reduces anxiety and depression as well as improves overall survival in  de novo  acute myelocytic leukemia patients who underwent chemotherapy: a randomized, controlled study
%A Hongxia Bao
%A Longrui Pan
%A Min Li
%A Xuena Zheng
%A Yalin Chen
%J SCIE-indexed Journal
%D 2019
%R 10.21037/27313
%X Acute myeloid leukemia (AML) is a malignant hematopoietic disorder characterized by the clonal expansion of undifferentiated myeloid precursors, leading to bone marrow (BM) failure and subsequently impairing hematopoiesis (1). As acute leukemia, AML develops quickly and is typically fatal within weeks or months if left untreated (1,2). According to the Global Burden of Disease Study [2015], about one million people globally are affected by AML and 147,000 AML-induced deaths occur in 2015 (3,4). AML patients are often accompanied with various bothersome symptoms, including fatigue, shortness of breath, bone pain or tenderness, easy bruising and bleeding, fever, weight loss and so on (2). And these are associated with decreased physical and social activities, poor body image and low socioeconomic status, thereby directly and negatively impact psychosocial wellbeing in AML patients (1,5). In addition, although current treatment strategies of AML are diversified, chemotherapy is still the cornerstone of AML treatment to achieve disease remission and prolong survival. However, a wide range of side effects (e.g., nausea, vomiting, constipation, anemia, hair loss, or even secondary neoplasm) induced by chemotherapy may further deteriorate the emotional, cognitive and social functions of AML patients, and consequently lead to the occurrence of mental disorders (6-9). Previous studies have elucidated that due to the substantial symptom burden of AML and its treatment, anxiety and depression are the most frequent psychological disorders in AML patients, especially for those who were newly diagnosed (10,11). Moreover, anxiety and depression are reported to worsen the prognosis in AML patients (12-14). Thus, incorporating psychosocial interventions into usual care is necessary to help achieve better prognosis in de novo AML patients undergoing chemotherapy
%U http://tcr.amegroups.com/article/view/27313/html